The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
Open accessAbstract
BACKGROUND: Treatment of latent tuberculosis in patients infected with the human immunodeficiency virus (HIV) is efficacious, but few patients around the world receive such treatment. We evaluated three new regimens for latent tuberculosis that may be more potent and durable than standard isoniazid treatment. METHODS: We randomly assigned South African adults with HIV infection and a positive tuberculin skin test who were not taking antiretroviral therapy to receive rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks, rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks, isoniazid (300 mg) daily for up to 6 years (continuous isoniazid), or isoniazid (300 mg) daily for 6 months (control group). The primary end point was tuberculosis-free survival. RESULTS: The 1148 patients had a median age of 30 years and a median CD4 cell count of 484 per cubic millimeter. Incidence rates of active tuberculosis or death were 3.1 per 100 person-years in the rifapentine-isoniazid group, 2.9 per 100 person-years in the rifampin-isoniazid group, and 2.7 per 100 person-years in the continuous-isoniazid group, as compared with 3.6 per 100 person-years in the control group (P>0.05 for all comparisons). Serious adverse reactions were more common in the continuous-isoniazid group (18.4 per 100 person-years) than in the other treatment groups (8.7 to 15.4 per 100 person-years). Two of 58 isolates of Mycobacterium tuberculosis (3.4%) were found to have multidrug resistance. CONCLUSIONS: On the basis of the expected rates of tuberculosis in this population of HIV-infected adults, all secondary prophylactic regimens were effective. Neither a 3-month course of intermittent rifapentine or rifampin with isoniazid nor continuous isoniazid was superior to 6 months of isoniazid. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT00057122.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Treatment of latent tuberculosis infection in HIV infected persons
Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000171.pub3 · Cited by 713
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993) · The Lancet · doi:10.1016/0140-6736(93)91817-6 · Cited by 441
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60331-7 · Cited by 385
Samandari, T., Agizew, T. B., Nyirenda, S., Tedla, Z., Sibanda, T., Shang, N., Mosimaneotsile, B., Motsamai, O. I., Bozeman, L., Davis, M. K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60204-3 · Cited by 355
Bucher, H. C., Griffith, L. E., Guyatt, G. H., Sudre, P., Naef, M., Sendi, P., & Battegay, M. (1999) · Aids · doi:10.1097/00002030-199903110-00009 · Cited by 282
Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
Balcells, M. E., Thomas, S. L., Godfrey-Faussett, P., & Grant, A. D. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1205.050681 · Cited by 238
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
Mwinga, A., Hosp, M., Godfrey-Faussett, P., Quigley, M., Mwaba, P., Mugala, B. N., Nyirenda, O., Luo, N., Pobee, J., Elliott, A. M., et al. (1998) · AIDS · doi:10.1097/00002030-199818000-00014 · Cited by 211
Cited by
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
The TEMPRANO ANRS 12136 Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507198 · Cited by 1,242
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N., Gordin, F., Bliven-Sizemore, E., Hackman, J., Hamilton, C. D., Menzies, D., Kerrigan, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104875 · Cited by 977
Self-citationLatent Mycobacterium tuberculosis Infection
Getahun, H., Matteelli, A., Chaisson, R. E., & Raviglione, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1405427 · Cited by 775
Self-citationZumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1200894 · Cited by 698
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6901a1 · Cited by 495
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Menzies, D., Adjobimey, M., Ruslami, R., Trajman, A., Sow, O., Kim, H., Obeng Baah, J., Marks, G. B., Long, R., Hoeppner, V., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714283 · Cited by 383
Tuberculosis and HIV Coinfection: Table 1.
Bruchfeld, J., Correia-Neves, M., & Källenius, G. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017871 · Cited by 378
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Swindells, S., Ramchandani, R., Gupta, A., Benson, C. A., Leon-Cruz, J., Mwelase, N., Jean Juste, M. A., Lama, J. R., Valencia, J., Omoz-Oarhe, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806808 · Cited by 363
Self-citationScaling up interventions to achieve global tuberculosis control: progress and new developments
Raviglione, M., Marais, B., Floyd, K., Lönnroth, K., Getahun, H., Migliori, G. B., Harries, A. D., Nunn, P., Lienhardt, C., Graham, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60727-2 · Cited by 340
Updates on the risk factors for latent tuberculosis reactivation and their managements
Ai, J.-W., Ruan, Q.-L., Liu, Q.-H., & Zhang, W.-H. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.10 · Cited by 298
Rangaka, M. X., Wilkinson, R. J., Boulle, A., Glynn, J. R., Fielding, K., van Cutsem, G., Wilkinson, K. A., Goliath, R., Mathee, S., Goemaere, E., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60162-8 · Cited by 262
A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control
Churchyard, G. J., Fielding, K. L., Lewis, J. J., Coetzee, L., Corbett, E. L., Godfrey-Faussett, P., Hayes, R. J., Chaisson, R. E., & Grant, A. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1214289 · Cited by 238
Self-citationScientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01379-x · Cited by 87
Self-citation
Metadata
- Authors
- Martinson, N. A., Barnes, G. L., Moulton, L. H., Msandiwa, R., Hausler, H., Ram, M., McIntyre, J. A., Gray, G. E., & Chaisson, R. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-07-07
- Volume
- 365
- Issue
- 1
- Pages
- 11-20
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166112014
- Cited by
- 385
- References
- 21
- FWCI
- 21.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.